Skip to main content
    R

    Revolution Medicines Inc (RVMD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $166.87
    -5.42 (-3.15%)

    Market Cap: $37.27B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Revolution Medicines Inc (RVMD) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Revolution Medicines are Roivant Sciences (ROIV), Insmed (INSM) and Royalty Pharma Plc (RPRX). By market cap, Revolution Medicines ranks 5th of the 13 companies on this page; Moderna (MRNA) is the largest at $90.38B. The median P/E of the 6 companies with a P/E is 34.7x.

    Peer Comparison

    RVMD's ROIC of -52.1% is below the peer median of 4.8%, and its revenue growth of -95.2% is below the median of 43.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Revolution Medicines (RVMD)$37.27BN/A181.6x0.0%-52.1%-95.2%0.00%
    Roivant Sciences Ltd (ROIV)$28.64BN/A679.3x0.0%N/A2136.0%0.00%
    Insmed Inc (INSM)$26.58BN/A17.7x-39.9%-44.2%268.4%0.00%
    Royalty Pharma Plc (RPRX)$39.85B12.9x11.7x25.7%7.6%13.3%1.37%
    Exelixis Inc (EXEL)$16.84B19.3x6.9x35.4%N/A10.2%0.00%
    BeOne Medicines AG (ONC)$47.58B50.0x18.7x13.9%7.5%33.8%0.00%
    Genmab AS (GMAB)$31.67B35.8x19.2x17.0%4.8%16.1%0.00%
    argenx NV ADR (ARGX)$60.37B33.5x6.1x31.7%N/A52.1%0.00%
    BridgeBio Pharma Inc (BBIO)$15.25BN/A16.0x-59.8%-33.0%192.6%0.00%
    Moderna Inc (MRNA)$90.38BN/A34.2x-110.5%-28.9%29.2%0.00%
    Ascendis Pharma AS (ASND)$18.06BN/A13.5x72.9%12.4%73.0%0.00%
    Praxis Precision Medicines Inc (PRAX)$9.17BN/AN/A0.0%N/A1349.0%0.00%
    Krystal Biotech Inc (KRYS)$9.05B40.4x18.8x47.9%N/A30.2%0.00%
    Peer median$27.61B34.7x17.7x15.4%4.8%43.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Revolution Medicines, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Roivant Sciences Ltd (ROIV)
    Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive...
    ROIV competitors
    Insmed Inc (INSM)
    Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases.
    INSM competitors
    Royalty Pharma Plc (RPRX)
    Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States.
    RPRX competitors
    Exelixis Inc (EXEL)
    Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development...
    EXEL competitors
    BeOne Medicines AG (ONC)
    BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe...
    ONC competitors
    Genmab AS (GMAB)
    Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
    GMAB competitors
    argenx NV ADR (ARGX)
    argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases...
    ARGX competitors
    BridgeBio Pharma Inc (BBIO)
    BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases.
    BBIO competitors
    Moderna Inc (MRNA)
    Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology...
    MRNA competitors
    Ascendis Pharma AS (ASND)
    Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
    ASND competitors
    Praxis Precision Medicines Inc (PRAX)
    Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal...
    PRAX competitors
    Krystal Biotech Inc (KRYS)
    Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United...
    KRYS competitors

    Frequently Asked Questions About RVMD

    Who are Revolution Medicines' main competitors?

    The companies most similar to Revolution Medicines include Roivant Sciences (ROIV), Insmed (INSM), Royalty Pharma Plc (RPRX), Exelixis (EXEL) and BeOne Medicines AG (ONC), listed from the closest match.

    Who is Revolution Medicines' biggest competitor?

    Moderna (MRNA) is the largest of the similar companies at $90.38B; Roivant Sciences (ROIV) is the closest match by business profile, size, sector and industry.

    How does RVMD stock compare with its competitors?

    RVMD's P/S is 181.6x against a peer median of 17.7x; its net margin is 0.0% against a peer median of 15.4%.

    Which of Revolution Medicines' competitors pays a higher dividend?

    Revolution Medicines pays no dividend. Royalty Pharma Plc (RPRX) has a higher forward dividend yield; Royalty Pharma Plc (RPRX) has the highest at 1.37%.

    Is Revolution Medicines bigger than its competitors?

    No. Revolution Medicines is 5th by market cap among the 13 companies on this page; the largest is Moderna (MRNA) at $90.38B.